 
Document Type:  Clinical Study Protocol 
Official Title:  A single arm, open-label, multicenter Phase [ADDRESS_815658] been treated in a previous Bayer-
sponsored regorafenib study (monotherapy or combination treatment) that has  reached the primary completion endpoint or the 
main data analysis, or has been stopped prematurely. 
Study ID: [REMOVED] 
Document Date:  20 NOV 2018 
 
CONFIDENTIAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1
Title Page
Protocol title:A single arm, open -label, multicenter Phase [ADDRESS_815659] been treated in a previous 
Bayer-sponsored regorafenib study  (monotherapy or combination 
treatment) that has reached the primary  completion endpoint or 
the main data anal ysis, or has been stopped prematurely .
Protocol number: [ZIP_CODE]
Compound Number: BAY 73 -4506
Study phase: Phase 2
Short title: Regorafenib rollover study .
Sponsor Name [CONTACT_29560]:Sponsor (Non -US): [COMPANY_014], D -[ZIP_CODE] Leverkusen, German y
Sponsor (US territory): Ba yer HealthCare Pharmaceuticals Inc., 
[ADDRESS_815660], [PO_BOX], Whippany , New Jersey  
[ZIP_CODE]- 0915, [LOCATION_003]
Regulatory Agency Identifier Number(s):EudraCT   2018-003650-24
Approval Date:20NOV 2018
The information provided in this document is strictly confidential and is intended solely for the performance of 
the clinical investigation.  Reproduction or disclosure of this document, whether in part or in full, to parties not 
associated with the clinical investigation or its use for any other purpose w ithout the prior written consent of the 
sponsor is not permitted.
Throughout this document, symbols indicating proprietary names (®, TM) may not be displayed. Hence, the 
appearance of product names without these symbols does not imply that these names are not protected.
CONFIDENTrAL 
Sponsor Signatory 
 Clinical Study Protocol 
BAY 73-[ADDRESS_815661] Information will be provided separately. Page 2 of43 
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
CONFIDENTIAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 3of 43
Protocol Amendment Summary of Changes Table
DOCUMENT HISTORY
Document Date
Amendm ent 1 20NOV 2018
Original Protocol 27 SEP 2018
Amendment 1 (20 NOV 2018 )
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council of the European Union .
Overall Rationale for the Amendment:
Section # 
and NameDescription of Change Brief Rationale
Synopsis, 3, 
9, 9.1, 
9.4.1, 9.4.2Safety  was upgraded to a 
second primary  objective and a 
respective endpoint was added to the protocol. A respective endpoint was also added for the 
secondary  objective tolerability .These updates were done to ensure compliance with posting requirements on CT.gov following a review of the initial Protocol Registration Form.
[ADDRESS_815662] of 4 initial feeder studies in Section 11 was removed.The feeder protocol titles were removed from the section “References” to avoid any future amendments to enable 
participants of other than the currently  
considered regorafenib studies to enter this roll -over study .
CONFIDENTIAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 4of 43
Table of Contents
Title Page ................................................................................................................................... 1
Sponsor Signatory .................................................................................................................... 2
Protocol Ame ndment Summary of Changes Table ............................................................... 3
Table of Tables ......................................................................................................................... 6
Table of Figures........................................................................................................................ 61.Protocol Summary ............................................................................................................ 7
1.1 Synopsis ........................................................................................................................... 7
1.2 Schema ............................................................................................................................. 8
1.3 Schedule of Activities (SoA) ........................................................................................... 9
2. Introduction ..................................................................................................................... 11
2.1 Study  Rationale .............................................................................................................. 11
2.2 Back ground .................................................................................................................... 11
2.3 Benefit/Risk Assessment ............................................................................................... 11
3.Objectives and Endpoints ............................................................................................... 12
4.Study Design .................................................................................................................... 12
4.1 Overall Design ............................................................................................................... 12
4.2 Scientific rationale for Study  Design ............................................................................. 13
4.3 Justification for Dose ..................................................................................................... 14
4.4 End of Study  Definition ................................................................................................. 14
5.Study Population ............................................................................................................. 14
5.1 Inclusion Criteria ........................................................................................................... 14
5.2 Exclusion Criteria .......................................................................................................... 15
5.3 Lifesty le Considerations ................................................................................................ 16
5.4 Screen Failures ............................................................................................................... 16
6.Study Intervention .......................................................................................................... 16
6.1 Study  Intervention(s) Administered ............................................................................... 17
6.2 Preparation/Handling/Storage/Accountability ............................................................... 17
6.3 Measures to Minimize Bias: Randomization and Blinding ........................................... 17
6.4 Study  Intervention Compliance ..................................................................................... 17
6.5 Concomitant Therap y .................................................................................................... 17
6.5.1 Drug -drug interactions relevant for regorafenib......................................................... 18
6.5.2 Permitted concomitant therapi[INVESTIGATOR_014] ................................................................................ 19
6.5.3 Prohibited prior and concomitant therapi[INVESTIGATOR_014] ................................................................ 20
6.5.4 Documentation of prior and new concomitant therapi[INVESTIGATOR_014] ............................................ 21
6.6 Dose Modification ......................................................................................................... 21
6.7 Intervention after the End of the Study .......................................................................... 25
7. Discontinuation of Study Intervention and Participant
Discontinuation/Withdrawal .......................................................................................... 25
7.1 Discontinuation of Study I ntervention ........................................................................... 25
7.1.1 Temporary  Discontinuation ........................................................................................ 26
7.1.2 Rechallenge ................................................................................................................ 26
7.2 Participant Discontinuation/Withdrawal from the Study ............................................... [ADDRESS_815663] to Follow up ........................................................................................................... 26
CONFIDENTIAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 5of 43
8.Study Assessments and Procedures ............................................................................... 27
8.1 Efficacy  Assessments .................................................................................................... 27
8.2 Safety  Assessments ........................................................................................................ 27
8.3 Adverse Events and Serious Adverse Events ................................................................ 27
8.3.1 Time Period and Frequency  for Collecting AE and SAE Information ....................... 28
8.3.2 Method of Detecting AEs and SAEs .......................................................................... 28
8.3.3 Follow -up of AEs and SAEs ...................................................................................... 28
8.3.4 Regulatory  Reporting Requirements for SAEs .......................................................... 28
8.3.5 Pregnancy ................................................................................................................... 29
8.4 Treatmen t of Overdose .................................................................................................. 29
8.5 Pharmacokinetics ........................................................................................................... 30
8.6 Pharmacod ynamics ........................................................................................................ 30
8.7 Gene tics......................................................................................................................... 30
8.8 Biomarkers ..................................................................................................................... 30
8.9 Medical Resource Utilization and Health Economics ................................................... 30
9. Statistical Considerations ............................................................................................... 30
9.1 Statistical Hy potheses .................................................................................................... 30
9.2 Sample Size Determination ........................................................................................... 30
9.3 Populations for Analy ses............................................................................................... 30
9.4 Statistical Analy ses........................................................................................................ 31
9.4.1 Efficacy  Anal yses....................................................................................................... 31
9.4.2 Safety  Anal yses.......................................................................................................... 31
9.4.3 Other Anal yses........................................................................................................... 31
9.5 Interim Anal yses............................................................................................................ 31
10. Supporting Documentation and Operational Considerations .................................... 3110.1 Appendix 1: Regulatory , Ethical, and Study  Oversight Considerations ........................ 31
10.1.1 Regulatory  and Ethical Considerations ...................................................................... 31
10.1.2 Financial Disclosure ................................................................................................... 32
10.1.3 Informed Consent Process .......................................................................................... 32
10.1.4 Data Protection ........................................................................................................... 32
10.1.5 Dissemination of Clinical Study  Data ........................................................................ 33
10.1.6 Data Qualit y Assurance .............................................................................................. 33
10.1.7 Source Documents ...................................................................................................... 34
10.1.8 Study  and Site Closure ............................................................................................... 34
10.1.9 Publication Policy ....................................................................................................... 34
10.2 Appendix 2: Clinical L aboratory  Tests .......................................................................... 34
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, 
Follow -up, and Reporting .............................................................................................. 34
10.3.1 Definition of AE ......................................................................................................... 34
10.3.2 Definition of SAE ....................................................................................................... 35
10.3.3 Recording and Follow-Up of AE and/or SAE............................................................ 36
10.3.4 Reporting of SAEs ...................................................................................................... 38
10.4 Appendix 4: Contraceptive Guidance and Collection of Pregnancy  Information ......... 40
10.5 Appendix 5: Abbreviations............................................................................................ 4210.6 Appendix 6 CYP3A4 inducers and inhibitors ............................................................... 43
11.References ........................................................................................................................ 43
CONFIDENTIAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 6of 43
Table of Tables
Table 1–1: Schedule of activities ............................................................................................... 9
Table 6–1:  Dose modification levels for regorafenib .............................................................. 21
Table 6–2:  Dose Modification/Delay  for Toxicities Related to Study  Drug (Except Hand Foot 
Skin Reaction, Hy pertension, and ALT and/or AST increases)a,c......................... 22
Table 6–3:  Dose modifications for HFSR related to regorafenib (dose expansion phase) 
(“Palmar -plantar ery thrody sesthesia sy ndrome”) ................................................. 23
Table 6–4:  Recommended dose modification and measures for hy pertension ....................... 24
Table 6–5:  Dose modification/interruption for ALT/AST increases related to regorafenib ... 25
Table 10–1:  An overview of CYP3A4 inducers and strong CYP3A4 inhibitors.................... 43
Table of FiguresFigure 1 –1:  Study  schema ......................................................................................................... 8
CONFIDENTIAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 7of 43
1. Protocol Summary
1.1 Synopsis
Protocol Title: A single arm, open- label, multicenter Phase [ADDRESS_815664] been treated in a previous Bay er-sponsored regorafenib study  
(monotherap y or combination treatment) that has reached the primary completion endpoint , or 
main data anal ysis, or has been stopped prematurely .
Short Title: Regorafenib rollover study
Rationale: The primary  purpose of the study  is to enable participants, currently  receiving 
regorafenib in a Bay er-sponsored clinical trial, to continue treatment after their respective 
study  has reached the primary  completion endpoint, main data anal ysis, or has been stopped 
prematurel y, and the respective data have been cleaned.  Participants will be able to continue 
treatment until the treating ph ysician feels the participant is no longer benefiting from 
treatment.
Objectives 
Objectives
Primary
The primary  purpos e of the program is to enable participants, currentl y receiving 
regorafenib in a Bayer-sponsored clinical trial and assessed by  [CONTACT_1961] ( PI)to be benefitting, to continue regorafenib treatment after their 
respective stud y has reached th e primary  completion endpoint , ormain data anal ysis, 
or has been stopped prematurel y.
And the documentation of safet y 
Secondary
Documentation of tolerability
Overall Design:
This is an open- label study  that will enable participants currentl y receiving regorafenib in a 
completed Bay er-sponsored regorafenib clinical trial to continue treatment.  A completed 
study  is defined as one that has reached the primary  completion endpoint ,ormain data 
analysis,or has been stopped prematurel y, and the respective data have been cleaned .
Disclosure Statement: This is an open -label stud y that will enable participants currentl y 
receiving regorafenib in a completed Bay er-sponsored regorafenib clinical trial to continue 
treatment .
Number of Participants:
Participants who are currently  receiving treatment in on -going regorafenib studies may  be 
eligible to enroll in the study . There may  be periods when there are no active participants in 
this study  but it will remain open for enrollment.
CONFIDENTIAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 8of 43
Intervention Groups and Duration:
The start of the treatmen t period is defined by  [CONTACT_614966] . Participants will be treated in 28- day cycles (ie, 3 weeks on, 1 week off) with 
once dail y oral administration of regorafenib .  Participants will continue regorafenib tre atment 
until any  of the discontinuation criteria specified in Section 7.2occur. 
After permanent discontinuation from the study , an end of treatment (EoT) visit will be 
performed within [ADDRESS_815665] dose of regorafenib was administered.
Data Monitoring Committee: No
1.2 Schema
The design of the stud y is represented in Figure 1–1.
Figure 1–1:  Study s chema

CONFIDENTIAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 9of 43
1.3 Schedule of Activities (SoA)
Table 1–1: Schedule of activities
Procedure ScreeningaIntervention Periodb[Cycles 
consisting of 4 weeks]End of study 
treatment
(up to [ADDRESS_815666] 
dose) Safety 
Follow -up 
(30-35days 
after last 
dose, 
phone call )Notes
Cycle 1 Day 1cCycle 4 Day 1 
+ every 3 months
(+/-1 week) 
Informed consent X
Inclusion and exclusion 
criteriaX Including pregnancy test done by 
[CONTACT_35425].
Demography X
Tumor type X
Medical histor y X Medical important events, e.g. Grade 3/4 (S)AEs, since the start of 
treatment in the feeder study should be reported as medical history  in 
this rollover study.
Study treatment →→→→→→→ Recheck clinical status before 1st dose of study medication.Regorafenib dosing as per feeder study protocol. 
Drug dispensing X X
Drug accountability X X X
AE review X X X X X To be documented only: 
AEs leading to dose 
reduction, interruption/delay 
and discontinuation
Any ongoing Grade [ADDRESS_815667] vital organs (e.g. heart, liver) per feeder study protocol CTCAE version. These events need to be re -
graded by [CONTACT_614967] 73 -4506 / [ZIP_CODE]
Amendment 1 Page 10of 43
according to CTCAE Ver 5.0.  
Any new CTCAE Ver 5.[ADDRESS_815668] vital organs 
(e.g. heart, liver) 
SAE review X X X X X To be documented any ongoing or new SAEs
Concomitant medication reviewX X X X X
Abbreviations:  AE -adverse event; CTCAE - Common terminology criteria for adverse events; SAE -serious adverse event.
a  During the screening period the participant will be on treatment under the umbrella of the feeder study. At the end of treatm ent visit of the feeder study,   eligibility criteria 
will be reviewed and the participants should sign informed consent for the rollover study.  
b  Safety assessments should be done according to local standard of care and regorafenib label information by [CONTACT_387283].
c  The treating investigator should ensure a seamless transition without a change in the treatment sched ule.  Any treatment interruption should not exceed 28 consecutive 
days including 1 week break.
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 11of 43
2. Introduction
Experience has shown that in nearl y all clinical trials with regorafenib (Stivarga®) there are 
participants who are continuing to receive regorafenib after the study  has been completed. A 
completed study  is defined as one that has reached the primary  completion endpoint, main 
data anal ysis, or has been stopped prematurel y, and the respective data have been cleaned. 
The intention of this rollover study  is to enable these participants who are still benefiting from 
treatment to continue to receive regorafenib treatment.
2.[ADDRESS_815669] 
been cleaned.  Participants will be able to continue treatment until the treating ph ysician feels 
the participant is no longer benefiting from treatment.
2.2 Background
Approved indications of regorafenib include pre -treated metastatic colorectal cancer (CRC) , 
hepatocellular carcinoma (HCC) , and gastro- intestinal stromal tumors (GIST). Regorafenib is 
currentl y being studied in multiple solid tumors. This rollover study  encompasses Phase [ADDRESS_815670] been cleaned,
and are onl y kept open to ensure treatment of participants who are still benefiting from 
regorafenib treatment.
2.3 Benefit/Risk Assessment
Only  participants who have been treated in a previous Bayer-sponsored regorafenib study  and 
are still benefiting from treatment will be allowed to be enrolled in this study. They  will 
continue treatment on the dose level that has been well tolerated before. 
The site’s principal investigator [INVESTIGATOR_614953] b study  to which the subject is initially  
assigned, is expected to assess the overall benefit/risk for each participant. When the 
investigator deems there is a positive benefit/risk assessment the participant can be included in this rollover study .
More de tailed information about the known and expected benefits and risks and reasonabl y 
expected adverse events of regorafenib may be found in the Investigator’s Brochure (IB).
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 12of 43
3. Objectives and Endpoints
Objectives Endpoints
Primary
The primary  purpose of the program is to 
enable participants, currently  receiving 
regorafenib in a Bay er sponsored clinical 
trial and assessed b y the PI  [INVESTIGATOR_614954], to continue regorafenib 
treatment after their respective study  has 
met its primary  completion date, or main 
data anal ysis, or has been stopped 
prematurel y.
And the documentation of safet y Frequency  and severity  ofSAEs 
and protocol -specified AEs 
Secondary
Documentation of tolerability Frequency  of dose modification s 
4. Study Design
This is an open- label study  that will enable participants currentl y receiving regorafenib in a 
completed Bay er-sponsored regorafenib clinical trial to continue treatment.  A completed 
study  is defined as one that has reached the primary  completion endpoint , main data anal ysis, 
or has been stopped prematurel y, and the respective data have been cleaned.   
4.1 Overall Design
The participants in this open -label program will continue receiving regorafenib monotherapy  
at the dose level previously  assigned under the f ollowing conditions:
as long as the interval of drug interruption does not exceed 4 weeks
as long as the treating physician feels the participant is continuing to benefit from 
treatment 
until he/she withdraws consent 
until he/she is non- compliant 
until he/she is lost to follow up 
until an unacceptable toxicity or death occurs
until patient starts a new anti- cancer treatment
until the development of a second malignancy
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 13of 43
participants with a beta human chorionic gonadotropin (beta -hCG ) test consistent with 
pregnancy . Pregnancy  will be reported along the same timelines as a serious adverse 
event (SAE) . 
Prior to receiving stud y medication for this rollover study , participants will be required to 
complete at least their EoT visit in their feeder study .  During this visit, criteria for the start of 
a subsequent cy cle of therapy , as determined b y the guidelines of the feeder protocol 
(eligibility  criteria) will be reviewed and the participants should sign informed consent for the 
rollover study . 
Participants should continue taking study medication dispensed under the umbrella of the 
feeder studies until first treatment in this rollover study . The participant needs to complete 
the last treatment cycle in the feeder study  and will start treatment in the rollover study  at 
Cycle [ADDRESS_815671] be recorded 
in the patient’s source documents and may be requested at the discretion of the Sponsor. 
The investigator will continuously  assess the benefit/risk of regorafenib treatment when the 
participant is seen in the clinic for his standard of care visits and will ensure that participants 
that achieve an y of the withdrawal conditions above discontinue treatment. 
Safety  assessments should be done according to local standard of care and regora fenib label 
information by [CONTACT_74079].
Following the EoT assessments from the feeder study , the following information will be 
recorded in the rollover study  eCRF: 
demograph y including study number , tumor ty pe,and participant’s identification 
number of the feeder study  
medical history : medical important events, e.g. Grade 3/4 (S)AEs, since the start of 
treatment in the feeder study  should be reported as  medical history  in this rollover 
study  
any ongoing or new SAEs 
any AEs leading to dose r eduction, interruption/delay  and discontinuation of 
regorafenib
any on-going Grade 3 / [ADDRESS_815672] vital organs (e.g. heart, 
liver) per feeder study CTCAE version. These events need to be re -graded by  [CONTACT_614968] 5.0.
new CTCAE Ver 5.[ADDRESS_815673] vital organs (e.g. 
heart, liver)
concomitant medications 
4.2 Scientific rationale for Study Design
Not applicable for this rollover study .
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ADDRESS_815674] completed the study  if he/she has discontinued treatment 
and/or has completed the Safety  Follow -up visit .
The end of the stud y is defined as the date when the last participant has completed the study  
and the sponsor has decided to close enrollment .
5. Study Population
Participants who remain ongoing in a Bayer-sponsored Clinical Trial that has reached the 
primary  completion date for data anal ysis and, in the opi[INVESTIGATOR_594780], are still 
benefiting from regorafenib treatment, will be eligible for entry  into this study . The feeder 
studies must have completed all submissions and related regulatory  requirements, e.g. [ADDRESS_815675] y:
Age
1.Participant must be age-eligible in the feeder stud yat the time of signing the informed 
consent.
Type of Participant and Disease Char acteristics
2.Participant is currentl y participating in an y Bayer-sponsored regorafenib study  and is 
receiving stud y treatment .
3.Participant is currently benefiting from treatment with regorafenib monotherap y and 
meets criteria to initiate a subsequent cy cleof therapy , as determined by  [CONTACT_614969].
4.Any ongoing adverse events that require temporary  treatment interruption must be 
resolved to baseline grade or assessed as stable and not requiring further treatment 
interruption by  [CONTACT_093].
Sex
5.Male or female
Contraceptive use b y men or women should be consistent with local regulations regarding 
the methods of contraception for those participating in clinical studies. This applies for the 
time between signing of the informed con sent form and [ADDRESS_815676] 
administration of the study  intervention.
Male participants:
In addition to the above methods, male trial participants and male partners of female 
trial participants must also use condoms during sex as an extra measure of protection 
against pregnancy .
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 15of 43
Female participants:
The investigator or a designated associate is requested to advise sexually  active 
participants on how to achieve highl y effective birth control using one or more of 
the following methods:
Hormonal contraception associated with inhibition of ovulation containing both 
estrogen and progestogen (oral, intravaginal or transdermal)
Hormonal contraception associated with inhibition of ovulation containing only  
progestogen (oral, injectable or implantable)
Intrauterine device (IUD) or intrauterine hormone- releasing s ystem (IUS)
Bilateral tubal occlusion
Vasectomized partner (provided that partner is the sole sexual partner of the woman of childbearing potential who is the trial participant and that the 
vasec tomized partner has received medical assessment of surgical success)
Women not considered to be of childbearing potential include those who biologicall y 
sterile, permanently  sterilized (e.g. tubal occlusion, hy sterectom y, bilateral 
salpi[INVESTIGATOR_1656] ) or postm enopausal. Postmenopausal women are defined as no menses 
for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may  be used to confirm a 
postmenopausal state in women not using hormonal contraception or hormonal replacement therap y. However in the absence of 12 months of amenorrhea, a single 
FSH measurement is insufficient.
Informed Consent
6. Capable of giving signed informed consent as described in Appendix 1 (Section 10.1) 
which includes compliance with the requirements and restrictions listed in the informed 
consent form (I CF) and in this protocol
5.2 Exclusion Criteria
Participants are excluded from the study  ifany of the following criteria apply :
Medical Conditions
1.Ineligibility , for medical reasons, to start the next cy cle in the respective feeder study
2. Patients with a beta-hCG test consistent with pregnancy .
Prior/Concomitant Therapy
3.Participants are using on e or more of the prohibited medications listed in the 
respective feeder stud y protocol. A comprehensive list can be found in Section 6.5. 
Prior/Con current Clinical Study Experience
4.Participant has been previously  permanently  discontinued from regorafenib treatment.
Diagnostic assessments
Not Applicable for this study .
Other Exclusions
5.Participant is unable to comply  with the requirements of the study . 
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 16of 43
5.3 Lifestyle Considerations
Not Applicable for this study .
5.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  entered in the study . A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants to meet the Consolidated 
Standards of Reporting Trials (CONSORT) publishing requirements and to respon d to queries 
from regulatory  authorities. Minimal information includes demograph y, screen failure details, 
eligibility  criteria, and any  SAE.
Individuals who do not meet the criteria for participation in this study  (screen failure) may  not 
be rescreened. 
6. Study Intervention
The following investigational products will be used in the study :
Regorafenib, 20 mg tablets 
Regorafenib, [ADDRESS_815677] cycle of the feeder 
study . They  will r eceive either 60, 80, 120, or 160 mg orall y (p.o.) every  day (qd) for 3 weeks 
of every  4 week cy cle (i.e. 3 weeks on, 1 week off).
Study  drug should be taken within 2 hours after a light meal with approximately  240 mL 
(8 fluid ounces) of water, preferabl yin the morning. If necessary , the study  drug may  be taken 
at different times of the day , but there should be consistency  with respect to dosing intervals 
(the recommendation is to have at least a 20 hour interval between doses). 
If a dose of study  drug w ill be missed, the missed dose should be skipped (vomited tablets 
cannot be made up), and the next dose should be taken at the regular time. The subsequent 
dose of study  drug should not be doubled. The investigator should be informed if the dose of 
regoraf enib taken exceeded the scheduled dose.
Regorafenib will be provided by  [CONTACT_614970].  
The regorafenib 40 mg tablet is coated, not divisible, gray -orange -red, oval (length 16 mm, 
width 7, thickness 4.9- 5.6) and 472 mg each in total weight. The 4 0mg tablets are embossed 
with “40” on one side of the tablet ,and “BAYER” on the other side. The packaging 
configuration is 30 tablets regorafenib 40mg and a 3 g desiccant capsule per bottle of 
regorafenib 40 mg .
The regorafenib 20 mg tablet is coated, not divisible, gray -orange -red, round, biconvex 
(diameter 9mm, thickness 3.5- 4.0mm) and [ADDRESS_815678] conditions.
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 17of 43
6.1 Study Intervention(s) Administered
Participants will be treated with the regorafenib dose taken during the last cycle of the feeder 
study .
6.2 Preparation/Handling/Storage/Accountability
Regorafenib tablets will be packed in high density poly ethylene (HDPE) bottles with a white 
child resistant closure and induction seal. Each bottle includes a desiccant cartridge inside.
Once the drug has been received it has to be kept in a secure, dry  location. The tablets have to 
be stored in the original bottle according to the labelled storage advice. The tablets have to be stored in the original pack provided in order to protect from moisture and swallowed immediately  after they  have been taken out.  The bottle has to be kept tightly  closed after first 
opening and the desiccant has to remain in the bottle. Once the bottle is opened, th e tablets 
have to be discarded after [ADDRESS_815679] confirm the receipt 
of the drug b y signing the drug acknowledgment form.
The study  drug will be labeled according to the requirements of local law and legislation.  
Label text will be approved according to the sponsor’s agreed procedures, and a cop y of the 
labels will be made available to the study  site upon request.
For the stud y drug, a system of numbering in accordance with all requirements of Good 
Manufacturing Practice (GMP) will be used, ensuring that each dose of study  drug can be 
traced back to the respective bulk ware of th e ingredients.  L ists linking all numbering levels 
will be maintained by [CONTACT_456]’s clinical supplies Quality  Assurance group. 
A complete record of batch numbers and expi[INVESTIGATOR_614955].
For more information about study drug, please refer to the Investigator ’s Brochure.
6.3 Measures to Minimize Bias: Randomization and Blinding
Not applicable. This is an open-label stud y.
6.[ADDRESS_815680] udy intervention will be assessed at each visit. Compliance will 
be assessed b y counting returned tablets/capsules. Deviation(s) from the prescribed dosage 
regimen should be recorded in the eCRF.
6.[ADDRESS_815681]’s welfare, and which is not 
expected to interfere with the evaluation of the study  drug, may  be given at the discretion of 
the Investigator. All concomitant medications (including start/stop dates, dose frequency , 
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 18of 43
route of administration and indication) must be recorded in the subject’s source 
documentation, as well as in the appropriate pages of the CRF. 
6.5.1 Drug-drug interactions relevant for regorafenib
[IP_ADDRESS] Inhibitors / inducers of CYP3A4
Administration of ketoconazole (400 mg for 18 days),a strong CYP3A4 inhibitor, with a 
single dose of regorafenib (160 mg on Day 5) resulted in an increase in mean exposure (AUC) 
of regorafenib of approximately  33%, and a decrease in mean exposure of the active 
metabolites, M- 2 (N-oxide) and M -5 (N-oxide an d N-desmeth yl), of approximately  90%. It is 
recommended to avoid concomitant use of strong inhibitors of CYP3A4 activity 
(Appendix 10.6) as their influence on the steady- state exposure of regorafenib and its 
metabolites has not been studied.
Administration of rifampi[INVESTIGATOR_2513] (600 mg for 9 days), a strong CYP3A4 inducer, with a sin gle 
dose of regorafenib (160 mg on Day 7) resulted in a reduction in AUC of regorafenib of 
approximately  50%, a 3 -to 4-fold increase in mean exposure of the active metabolite M-5, 
and no change in exposure of active metabolite M -2. Other CYP3A4 inducers 
(Appendix 10.6) may  also increase metabolism of regorafenib. Inducers of CYP3A4 should 
be avoided, or selection of an alternate concomitant medicina l product, with no or 
minimal potential to induce CYP3A4 should be considered.Appendix 10.[ADDRESS_815682] commonly  used strong CYP3A4 inhibito rs 
and CYP3A4 inducers) that should be avoided during the stud y.
[IP_ADDRESS] UGT1A1 and UGT1A9 substrates 
In vitro data indicate that regorafenib as well as its active metabolites M -2 inhibit 
glucuronidation mediated by  [CONTACT_15924]1A1 and UGT1A9 whereas M -5 onl y inhibits UGT1A1 at 
concentrations which are achieved in vivo at steady  state. 
Administration of regorafenib with a 5 -day break prior to administration of irinotecan resulted 
in an increase of approximately  44% in mean exposure (AUC) of SN -38, a substrate of 
UGT1A1 an d an active metabolite of irinotecan. An increase in mean exposure (AUC) of 
irinotecan of approximately  28% was also observed. This indicates that co-administration of 
regorafenib may increase systemic exposure to UGT1A1 and UGT1A9 substrates. The 
clinical significance is unknown and is dependent on the substrate.
[IP_ADDRESS] Breast cancer resistance protein and P -glycoprotein substrates
Administration of regorafenib (160 mg for 14 days) prior to administration of a single dose of rosuvastatin (5 mg), a breast cancer r esistance protein (BCRP) substrate, resulted in a 3.9- fold 
increase in mean exposure (AUC) of rosuvastatin and a 4.6- fold increase in C
max. This 
indicates that co -administration of regorafenib may  increase the plasma concentrations of 
other concomitant BCR P substrates (e.g. methotrexate, fluvastatin, atorvastatin). Therefore, 
it is recommended to monitor patients closely for signs and symptoms of increased exposure to BCRP substrates. 
[IP_ADDRESS] CYP isoform -selective substrates
A cytochrome P450 enzyme (CYP) probe substrate study in cancer patients was conducted to 
evaluate the effect of regorafenib on the pharmacokinetics of CYP2C9 substrate warfarin (10 mg), CYP2C19 substrate omeprazole (40 mg), CYP3A4 substrate midazolam (2 mg) and 
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 19of 43
CYP2C8 substrate rosiglitazone (4 mg) and to provide information about potential changes in 
exposure of these substrates when administered with regorafenib.
Overall, the PK data suggest that regorafenib may be given concomitantly with substrates
of CYP3A4, CYP2C8, CYP2C9, and CYP2C19 without the expectation of a clinically 
meaningful drug interaction .
[IP_ADDRESS] Antibiotics
The concentration -time profile indicates that regorafenib and its metabolites may undergo 
enterohepatic circulation. Co- administration with neomy cin, a poor ly absorbed antimicrobial 
agent used for eradicating the gastrointestinal microflora (which may  interfere with the 
enterohepatic circulation of regorafenib) had no effect on the regorafenib exposure. There was 
an approximately  80% decrease in the exposure of the active metabolites M- [ADDRESS_815683] and potential interactions with other antibiotics is unknown, but may result in a 
decreased efficacy of regorafenib.
[IP_ADDRESS] Bile salt-sequestering agents
Bile salt -sequestering agents may  interact with regorafenib by  [CONTACT_614971] (or reabsorption), thus resulting in potentially decreased 
exposure. The clinical significance of these po tential interactions is unknown, but may 
result in a decreased efficacy of regorafenib.
6.5.2 Permitted concomitant therapi[INVESTIGATOR_614956] (including start / stop dates, total daily  dose, and indication) 
must be recorded in the patient’s source d ocumentation and in the eCRF.
Treatment with non -conventional therapi[INVESTIGATOR_014] (e.g. herbs or acupuncture) and 
vitamin/mineral supplements isacceptable provided that they  do not interfere with the 
study  endpoints, in the opi[INVESTIGATOR_871]. However, St John’s Wort (herbal 
preparation based on the plant species hypericum) is not permitted .
Patients who are therapeutically  treated with an agent such as warfarin or heparin or 
novel oral anticoagulants (NOACs) such as dabigatran or rivaroxaban will be allowe d 
to participate provided that no prior evidence of underly ing abnormalit y in coagulation 
parameters exists. Close monitoring of at least weekly  evaluations for patients on 
warfarin will be performed until I NR is stable based on a measurement that is pre -dose 
as defined b y the local standard of care.
P-glycoprotein substrates: clinical data indicate that regorafenib has no effect on 
digoxin pharmacokinetics, therefore can be given concomitantly  with p- glycoprotein 
substrates, such as digoxin, without a clinically  meaningful drug interaction (see 
Section [IP_ADDRESS]).
Patient s may  receive palliative or supportive care for an y underl ying illness (e.g., 
Megestrol acetate ( Megace®) as supportive care) . 
Palliative and supportive care for the other disease- related s ymptoms and for toxicity  
associated with treatment will be offered to all patients on this trial. The use of anti -
diarrheal or anti -emetics according to standard practice is strongl y encouraged.
Bisphosphonates and/or RANKL  inhibitor therapi[INVESTIGATOR_014] (such as denosumab) for bone 
metastases may  be continued if treatment with an agent from one of these two classes 
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 20of 43
was initiated prior to signing informed consent. Bisphosphon ates and/or RANKL 
inhibitor therapi[INVESTIGATOR_391445], unless 
in the opi[INVESTIGATOR_871], the patient does not have PD.
Radiotherap y:
oPalliative radiotherap y during the stud y isallowed for local pain control after 
individual benefit-risk assessment provided that:
In the opi[INVESTIGATOR_871], the patient does not have PD,
No more than 25% of the patient’s bone marrow is irradiated,
The radiation field does not encompass a lung field (to reduce the risk for ILD caused b y irradiation pneumonitis). 
oRegorafenib may  only be continued during palliative radiotherap y after an 
individual benefit-risk assessment. The investigator should consult the sponsor.
Note: administration of p alliative radiation therapy to a s ymptomatic solitary lesion or to 
the brain will be considered clinical progression 
Analgesics.
Nutritional support.
Major surgery  for any  reason different than sy mptom management or tumor control should 
only be performed during the study  period if, in the opi[INVESTIGATOR_614957] / risk assessment (taking into account the potential wound healing complications that have been described with all anti- VEGF drugs), the surgery  will be 
beneficial for the patient. I t is recommended to stop regorafenib treatment two weeks before 
surgery . The decision to resume regorafenib after surgery  should be based on clinical 
judgment of adequate wound healing. Patients should be placed back on study  therapy within 
4 weeks of the scheduled interruption of regorafenib. 
Note : 
if treatment interruption of regorafenib will be >[ADDRESS_815684] be discontinued from regorafenib. 
Patients may  receive oth er medications that the investigator deems to be medicall y necessary.
6.5.3 Prohibited prior and concomitant therapi[INVESTIGATOR_614958]:
Disease -specific anti -neoplastic therapi[INVESTIGATOR_014], including kinase inhibitors, 
immunotherapy , chemotherapy , or experimental therapi[INVESTIGATOR_614959]. 
Surgery  for s ymptom management or tumor control.
Strong CYP 3A4 inhibitors / inducers .Strong CYP3A4 inhibitors or CYP3A4 
inducers (See Appendix 10.6) are not allowed. 
Any drug that targets angiogenesis, especiall y VEGF and VEGFR.
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 21of 43
Tyrosine- kinase inhibitors (TKIs)
Antiviral treatment for HCV 
Bone marrow transplant or stem cell rescue.
Prior and concomitant palliative radiation therap y is allowed if the target lesion(s) are 
not included within the radiation field and no more than 25% of the bone marrow is 
irradiated.
Use of biologic response modifiers, such as granulocy te colony  stimulating factor (G -
CSF), within the 3 weeks prior to the randomization date. 
oG-CSF and other hematopoietic growth factors may  be used during the study  in the 
management of acute to xicity  such as febrile neutropenia when clinically  indicated 
or at the discretion of the investigator; however they  may  not be substituted for a 
required dose reduction. 
oPatients taking chronic erythropoietin are permitted.
Patients taking narrow therapeutic index medications (e.g., warfarin, quinidine, and 
cyclosporine) should be monitored proactivel y.
Investigational anti- tumor agents or anti -neoplastic chemo/hormonal/immunotherapy .
Therapeutic monitoring should be performed consistent with the l ocal clinical standard of care 
following dose modification of the agent. In general, patients should be closely  monitored for 
side effects of all concomitant medications regardless of path of elimination.
6.5.4 Documentation of prior and new concomitant therapi[INVESTIGATOR_614960] (including over -the-counter or prescription medicines, vitamins, 
and/or herbal supplements) that the participant is receiving at the time of enrollment or 
receives during the study must be recorded along with:
Reason for use
Dates of administration including start and end dates
Dosage information including dose and frequency
The Medical Monitor should be contact[CONTACT_43205] y questions regarding concomitant or 
prior therap y.
6.6 Dose Modification
In case a dose reduction is nece ssary , the study  treatment will be administered according to 
the following tables. Table 6–1shows the dose modification levels for regorafenib. Table 6–2,
Table 6–3, Table 6–4, and Table 6–5 show the dose modification plans for specific known 
drug-related toxicities.
Table 6–1:  Dose modification levels for regorafenib
Dose Level Daily Dose Number of tablets
Dose level 0 (standard dose) 160mg 4 tablets of regorafenib, 40 mg -tablet
Dose level -1 120mg 3 tablets of regorafenib, 40 mg -tablet
Dose level -2 80mg 2 tablets of regorafenib, 40 mg -tablet
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 22of 43
Table 6–2:  Dose Modification/Delay for Toxicities Related to Study Drug (Except 
Hand Foot Skin Reaction, Hypertension, and A LT and/or A ST increases)a,c
Grade of Event Dose 
InterruptionDose 
modificationDose for 
subsequent cycles
Grade 0 -2 Treat on time No change No change
Grade 3Delay until ≤ Grade 2bReduce 1 dose 
levelIf toxicity remains ≤Grade 2, 
dose re -escalation can be 
considered at the discretion of 
the treating investigator. If dose is re -escalated and 
toxicity ( ≤Grade 3) recurs, 
institute permanent dose 
reduction.
Grade 4Delay until ≤ Grade 2bReduce by 1 dose level.
Permanent discontinuation can be considered at 
treating investigator’s discretion.
Abbreviations: ALT –alanine transaminase; AST –aspartate transaminase 
a  Excludes alopecia, non -refractory nausea/vomiting, non -refractory hypersensitivity, non -clinically significant 
and asymptomatic laboratory abnormalities.
b  If no recovery after a 4 -week delay, treatment should be permanently discontinued. In the event of severe 
bleeding necessitating urgent medical intervention, permanent discontinuation of regorafenib should be 
considered.
c  In subjects who develop cardiac ischemia and/or infarction, interruption of regorafenib is recommended until resol ution. The decision to re -initiate regorafenib therapy should be based on careful consideration of the 
potential benefits and risks of the individual subject. Regorafenib should be permanently discontinued if there 
is no resolution.
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 23of 43
Table 6–3:  Dose modifications for HFSR related to regorafenib (dose expansion 
phase) (“Palmar -plantar erythrodysesthesia syndrome”)
Skin toxicity grade Occurrence Recommended dose modification and 
measures
Grade 1:Numbness, 
dysesthesia, paresthesia , 
tingling, painless swelling, 
erythema or discomfort of the 
hands or feet which does not disrupt the subject’s normal activitiesAny Maintain dose level and immediately institute 
supportive measures for symptomatic relief .
Grade 2:Painful erythema 
and swelling of the hands or 
feet and/or discomfort which affects the subject’s normal activities.1
stoccurrence Decrease dose by 40 mg (one tablet) and 
immediately institute supportive measures.If no improvement occurs despi [INVESTIGATOR_40808], interrupt therapy for a minimum of 7days, until toxicity resolves to Grade 0-1.
A dose re -escalation is permitted at the 
discretion of the treating physician.
No im provement 
within 7 days or 
2ndoccurrenceInterrupt therapy until toxicity resolves to 
Grade 0-1.  When resuming treatment, 
decrease dose by 40 mg (one tablet).  A 
dose re -escalation is permitted at the 
discretion of the treating physician.
3rdoccurrence Interrupt therapy until toxicity resolves to Grade 0-1.  When re suming treatment, 
decrease dose by 40 mg (one tablet).
A dose re -escalation is permitted at the 
discretion of the treating physician.
4thoccurrence Discontinue treatment.
Grade 3:Moist 
desquamation, ulceration, 
blistering or severe pain of 
the hands o r feet, or severe 
discomfort that causes the subject to be unable to work or perform activities of daily living.1
stoccurrence Institute supportive measures immediately.  Interrupt therapy for a minimum of 7 days 
until toxicity resolves to Grade 0-1.  When 
resuming treatment, decrease dose by 40mg (one tablet).  A dose re -escalation is 
permitted at the discretion of the treating physician.
2ndoccurrence Institute supportive measures immediately.  Interrupt therapy for a minimum of 7 days 
until toxicity resolves to Grade 0-1. When 
resuming treatment, decrease dose by 
40mg (one tablet).
3rdoccurrence Discontinue treatment.
Abbreviations:  HFSR –hand -foot-skin reaction
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 24of 43
Table 6–4:  Recommended dose modification and measures for hypertension
Hypertension 
gradeOccurrence Recommended dose modification and measuresa
Grade 1 Any Maintain dose level.
Consider increased BP monitoring.
Grade 2 Any Institute antihypertensive treatment with the aim to achieve 
diastolic BP ≤90mmHg:
If BP previously within normal limits, start 
antihypertensive monotherapy.
If subject already on antihypertensive medication, titrate up the dose. 
Continue regorafenib, or if sy mptomatic, hold regorafenib until 
symptoms resolve AND diastolic BP ≤90mmHg.
b
When regorafenib is restarted, continue at the same dose level.
Grade [ADDRESS_815685] occurrence Institute antihypertensive treatment with the aim to achieve 
diastolic BP ≤90mmHg:
Start antihypertensive medication 
AND/OR
Increase current antihypertensive medication
AND/OR 
Add additional antihypertensive medications. 
Hold regorafenib until diastolic BP ≤90mmHg, and if 
symptomatic, until sy mptoms resolve.b
When regorafenib is restarted, continue at the same dose level.
If BP is not controlled with the addition of new or more intensive 
therapy, reduce by 1 dose level.c
Re-occurrence If Grade 3 hypertension recurs despi[INVESTIGATOR_614961], reduce another dose level.d
Grade 4 Any Discontinue therapy
Abbreviations: BP = blood pressure.
a  A more conservative management of hypertension is allowed if judged medically appropriate by [CONTACT_093].
bSubjects requiring a delay of >[ADDRESS_815686] one full cycle, dose re -escalation is permitted at the investigator’s 
discretion.
dSubjects requiring >2 dose level reductions (<80 mg reduction) should go off regorafenib.
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 25of 43
Table 6–5:  Dose modification/interruption for A LT/A ST increases related to 
regorafenib
Observed elevations of 
ALT and / or A STOccurrence Recommended measures and dose 
modification
≤[ADDRESS_815687] Any occurrence Continue regorafenib treatment.  Monitor liver 
function weekly until transaminases return to 
<[ADDRESS_815688] or baseline.
>[ADDRESS_815689] to ≤[ADDRESS_815690] 1stoccurrence Interrupt regorafenib treatment.  Monitor transaminases weekly until return to <[ADDRESS_815691] or baseline.Restart:  If the potential benefit outweighs the risk of hepatotoxicity, re -initiate regorafenib 
treatment, reduce dose by 40 mg (one tablet), 
and monitor liver function weekly for at least 4weeks.
Re-occurrence Discontinue treatment with regorafenib 
permanently.
>[ADDRESS_815692] Any occurrence Discontinue treatment with regorafenib permanently.
>[ADDRESS_815693] with 
concurrent bilirubin >2 
times ULNAny occurrence Discontinue treatment with regorafenib 
permanently. Monitor liver function weekly until 
resolution or return to baseline.  Exception:  patients with Gilbert’s syndrome who 
develop elevated transaminases should be managed as per the above outlined 
recommen dations for the respective observed 
elevation of ALT and / or AST.
Abbreviations :ALT –alanine transaminase; AST – aspartate transaminase; ULN = upper limit of normal.
If a dose reduction has been performed within this study protocol intra subject dose 
reescalation can be considered up to the staring dose in this rollover study  protocol at the 
discretion of the treating phy sician.
6.7 Intervention after the End of the Study
There is no planned intervention following the end of the study .
7. Discontinuation of Study Intervention and Participant 
Discontinuation/W ithdrawal
7.[ADDRESS_815694] be withdrawn from the stud yintervention for the following reasons: 
At their own request or at the reques t of their legally  acceptable representative. At any  
time during the stud y and without giving reasons, a subject may decline to participate 
further. The subject will not suffer an y disadvantage as a result.
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 26of 43
If, in the investigator's opi[INVESTIGATOR_1649], continuation o f the study  would be harmful to the 
subject's well -being.
At the specific request of the sponsor and in liaison with the investigator (e.g. obvious 
non-compliance, safet y concerns).
Severe allergic reactions, such as exfoliate ery throderma, anaphy laxis, or vascular 
collapse.
Any other potential adverse reaction deemed sufficiently  serious to warrant 
discontinuation of treatment by  [CONTACT_614972](s).
Substantial non- compliance with the requirements of the study .
Use of il licit drugs or other substances that may , in the opi[INVESTIGATOR_871], 
have a reasonable chance of contributing to toxicity .
Development of an y intercurrent illness or situation which would, in the judgment of 
the investigator, may  affect assessments of clinical status and study endpoints to a 
relevant degree.
Clinical progression (e.g. defined as worsening of the ECOG PS ≥3 or sy mptomatic 
deterioration including increase in liver function tests).
The development of a second malignancy .
Subject lost to follow -up.
Interruption in study  drug administration for greater than 28 consecutive day s 
(including the 1 week drug holiday  in each cy cle).
More than 2 dose reductions of the study  drug are necessary .
Patients with a beta- human chorionic gonadotropin (hCG ) test consistent with pregnancy . 
Pregnancy  will be reported as an SAE using the Pregnancy  Monitoring Form .
7.1.[ADDRESS_815695] ing to criteria specified in Section 6.6. The interval of drug 
interruption should not exceed 4 weeks including 1 wee k break. 
7.2 Participant Discontinuation/Withdrawal from the Study
In case a participant is withdrawn from stu dy intervention he/she will be withdrawn from the 
study after the safet y follow -up visit .
7.[ADDRESS_815696] be taken if a participant fails to return to the clinic for a required 
study  visit:
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 27of 43
The site must attempt to contact [CONTACT_221728]/or should 
continue in the study .
Before a participant is deemed lost to follow up, the investigator or designee must 
make every  effort to r egain contact [CONTACT_6635] (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participant’s last known mailing address 
or local equivalent methods). These contact [CONTACT_21457]’s medic al record.
Should the participant continue to be unreachable, he/she will be considered lost to 
follow -up.
Discontinuation of specific sites or of the study  as a whole are handled as part of Appendix 1 
(Section 10.1).
8. Study Assessments and Procedures
Study  procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.
Immediate safety  concerns should be discussed with the sponsor immediately  upon 
occurrence or awareness to determine if the participant should continue or discontinue study  intervention.
Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study  conduct.
All screening activities must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log 
to record details of all participants screened and to confirm eligib ility or record 
reasons for screening failure, as applicable.
8.1 Efficacy Assessments
There will be no formal assessments of efficacy  during the rollover study .
8.2 Safety Assessments
Planned time points for all safety  assessments are provided in the SoA.
8.3 Adverse Events and Serious Adverse Events
The definitions of an AE or SAE can be found in Appendix 3 (Section 10.3).
AE will be reported b y the participant (or, when appropriate, b y a caregiver, surrogate, or the 
participant's legall y authorized representative or health care professional not involved in the 
study ).
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE . They remain responsible for 
following up SAEs, or AEs, considered related to the study  intervention or study  procedures, 
orthose that caused the participant to discontinue the study  (see Section 7).
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 28of 43
8.3.1 Time Period and Frequency for Collecting AE and SAE Information
All SAEs will be collected from the signing of the informed consent for m (ICF until the 
safet y follow -up visit (Section 1.3).
AEs,as described in the S oA, (ie,AEs leading to dose reduction, interruption/delay  and 
discontinuation and a ny new CTCAE Ver 5.[ADDRESS_815697] 
vital organs (e.g. heart, liver) will be collected from the signing of the ICF until the safety  
follow up-visit
Any ongoing Grade [ADDRESS_815698] vital organs (e.g. heart, liver) per 
feeder study  protocol CTCAE version need tobe reported as A Es in this rollover study .These
events need to be re -graded by  [CONTACT_614973] 5.0.
Medical important events, e.g. Grade 3/4 (S)AEs, since the start of treatment in the feeder 
study  should be reported as medical history  in this rollover study .
Medical occurrences that begin before the start of study  intervention but after obtaini ng 
informed consent will be recorded on the AE section of the case report form (CRF).
Medical occurrences that started before but deteriorated after obtaining informed consent will 
be recorded as adverse events. 
All SAEs will be recorded and reported to t he sponsor or designee immediately  and under no 
circumstance should this exceed 24 hours, as indicated in Appendix 3 (Section 10.3). The 
investigator will submit any updated SAE data to the sponsor within 24 hours of it being 
available.
Investigators are not obligated to activel y seek AE or SAE after conclusion of the study  
participation . However, if the investigator learns of an y SAE, incl uding a death, at an y time 
after a participant has been discharged from the study , and he/she considers the event to be 
reasonabl y related to the study  intervention or study  participation, the investigator must 
promptly  notify  the sponsor .
8.3.2 Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AE and SAE and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3 
(Section 10.3).
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.3.3 Follow-up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. All SAEs will be followed until resolution, 
stabilization, the event is otherwise explained, or the particip ant is lost to follow -up (as 
defined in Section 7.3). Further information on follow -up procedures is given in Appendix 3 
(Section 10.3).
8.3.4 Regulatory Reporting Requirements for SAEs
Prompt notification by  [CONTACT_614974] y of participants and the 
safet y of a stud y intervention under clinical investigation are met.
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 29of 43
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and 
other regulatory  agencies about the safet y of a study  intervention under clinical 
investigation. The sponsor will comply  with country -specific regulatory  requirements 
relating to safet y reporting to the regulatory  authority , Institutional Review Boards 
(IRB)/Independent Ethic s Committees (IEC) , and investigators.
Investigator safety  reports must be prepared for suspected unexpected serious adverse 
reactions (S[LOCATION_003]R) according to local regulatory  requirements and sponsor policy  and 
forwarded to investigators as necessary .
An investigator who receives an investigator safety report describing an SAE or other 
specific safet y information (eg, summary or listing of SAEs) from the sponsor will 
review and then file it along with the Investigator’s Brochure and will notify  the 
IRB/IEC , if appropriate according to local requirements.
8.3.5 Pregnancy
Details of all pregnancies in female participants and, if indicated, female partners of 
male participants will be collected after the start of study  intervention and until
2months after discontinuation of intervention.
If a pregnancy  is reported, the investigator should inform the sponsor within 24 hours 
of learning of the pregnancy and should follow the procedures outlined in Appendix 4 
(Section 10.4).
Abnormal pregnancy  outcomes (eg, spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy ) are considered SAEs.
8.4 Treatment of Overdose
For this study , any  dose of study  intervention greater than 160 mg within a 20-hour time 
period will be considered an overdose .
In the event of an overdose, the investigator/treating ph ysician should:
1.Closely  monitor the participant for an y AE/SAE and laboratory  abnormalities until 
study  intervention can no longer be detected s ystemically .
2.Obtain a plasma sample for PK anal ysis within [ADDRESS_815699] dose 
of study  intervention if requested by  [CONTACT_1689] (determined on a case -by-
case basis).
3.Any overdose or incorrect administration of study  drug should be noted on the 
Study  Drug Administration electronic Case Report Form (eCRF).
4.Adverse events associated with an overdose or incorrect administration of study  
drug should be recorded on the Adverse Event eCRF.
Decisions regarding dose interruptions or modifications will be made by  [CONTACT_55887].
For detailed guidance on overdosing please refer to the most current version of the IB for 
regorafenib.
There is no specific treatment for regorafenib overdose.  The highest dose of regorafenib 
studied clinically  is 220 mg QD.  The AEs observed at this dose were primarily  
dermatological events, hoarsen ess, diarrhea, mucositis, and nausea.  In the event of suspected 
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 30of 43
overdose regorafenib should be immediately withheld and supportive care instituted under the 
supervision of a qualified health care professional.  
There is no specific antidote for Stivarga®overdose.  Subjects who have overdosed should be 
treated with s ymptomatic support.  No additional data concerning management of overdose 
are available at this time. 
8.5 Pharmacokinetics
PK parameters are not evaluated in this study .
8.6 Pharmacodynamics
Pharmacody namic parameters are not evaluated in this study .
8.7 Genetics
Genetics are not evaluated in this study .
8.8 Biomarkers
Biomarkers are not evaluated in this study .
8.9 Medical Resource Utilization and Health Economics
Medical Resource Utilization and Health Economics are not evaluated in this study .
9. Statistical Considerations
Data from participant who are transferred to a rollover study  may  be pooled and anal yzed 
together with the data from the study  in which the participant was initially  included.
Data willbe analy zed using summary  or frequency  statistics or data listings.
9.1 Statistical Hypotheses
No confirmatory  statistical hy pothesis testing is planned. All safety  anal ysis will be done in a 
descriptive manner only.
9.2 Sample Size Determination
No formal sample size estimation will be done.
Participants of on -going or future feeder studies will be enrolled in the study; therefore the 
number of participants is not predictable. 
9.3 Populations for Analyses
For purposes of statistical analy sis, the following analysis sets are defined:
Analysis set Description
Enrolled All participants who sign edthe ICF
Safety All participants who take at least 1 dose of regorafenib within 
this rollover study .
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 31of 43
9.4 Statistical Analyses
The statistical anal ysis plan will be developed and finalized before database lock and will 
describe the analysissets and procedures for a ny missin gimputation method, if applicable .
Descriptive anal ysis/listings of data collected e.g. demography , medical history , drug 
accountability , concomitant medication, adverse events (including serious), dose 
modifications and reasons for termination of treatment may  be provided, as appropriate.
9.4.[ADDRESS_815700] safety  
information as specified in the SoA.  
10.1 Appendix 1: Regula tory, Ethical, and Study Oversight Considerations
10.1.1 Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences (CIOMS) International Ethical Guidelines
Applicable ICH Good Clinical Practice (GCP) Guidelines
Applicable laws and regulations
The protocol, protocol amendments, I CF, Investigator Brochure, and other relevant 
documents (eg, advertisements) must be submitted to an I RB/IEC by  [CONTACT_55892]/IEC before the study  is initiated.
Any amendments to the protocol will require IRB/I EC approval before 
implementation of changes made to the stud y design, except for changes necessary to 
eliminate an immediate hazard to study  participants.
The investigator will be responsible for the following:
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 32of 43
oProviding written summaries of the status of th e study  to the IRB/IEC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  [CONTACT_1201]/IEC
oNotify ing the IRB/IEC of SAEs or other significant safet y findings as required by 
[CONTACT_1744]/IEC procedures
oProviding overs ight of the conduct of the study  at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 
536/2014 for clinical studies (if applicable), and all other applicable local 
regulations
10.1.2 Financial Disclosure
Investigat ors and sub-investigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial certification or disclosure statements to the appropriate regulatory  authorities. Investigators 
are responsible for providing information on financial interests during the course of the stud y 
and for 1 year after completion of the study .
10.1.3 Informed Consent Process
The investigator or his/her representative will explain the nature of the study  to the 
participant or his/her legally  authorized representative and answer all questions 
regarding the stud y.
Participants must be informed that their participation is voluntary . Participants or their 
legally  authorized representative will be required to sign a statement of informed 
consent that meets the requirements of [ADDRESS_815701] (HIPAA) requirements, where 
applicable, and the IRB/IEC or study  center.
The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study  and the date the written 
consent was obtained. The authorized person obtaining the informed consent must also sign the ICF.
Partici pants must be re -consented to the most current version of the ICF(s) during 
their participation in the study .
A cop y of the ICF(s) must be provided to the participant or the participant’s legall y 
authorized representative.
10.1.4 Data Protection
Participants will be assigned a unique identifier by  [CONTACT_456]. Any  participant 
records or datasets that are transferred to the sponsor will contain the identifier only; participant names or an y information which would make the participant identifiable 
will not be transf erred.
The participant must be informed that his/her personal study -related data will be used 
by [CONTACT_10999]. The level of disclosure 
must also be explained to the participant.
The participant must be informed t hat his/her medical records may  be examined by  
[CONTACT_171138], by  [CONTACT_6667]/IEC members, and by  [CONTACT_55894].
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 33of 43
10.1.5 Dissemination of Clinical Study Data
Result Summaries of Bayer’s sponsored clinical trials in drug development phases 2, 3 and 4 
and phase 1 trials in patients are provided in the Bayer Trial Finder application after marketing authorization approval in line with the position of the global phar maceutical 
industry  associations laid down in the “Joint Position on the Disclosure of Clinical Trial 
Information via Clinical Trial Registries and Databases”. In addition results of clinical drug 
trials will be provided on the publicly  funded website www.ClinicalTrials.gov and EU 
Clinical Trials Register in line with the applicable regulations.
Bayer commits to sharing upon request from qualified scientific and medical researchers 
patient -level clinical trial data, study -level clinical trial data, and protocols from clinical trials 
in patients for medicines and indications approved in the [LOCATION_002] (US) and European 
Union (EU) on or after January  01, 2014 as necessary  for conducting legitimate research.
All Bay er-sponsored clinical trials are considered for publication in the scientific literature 
irrespective of whether the results of the clinical trials are positive or negative.
10.1.6 Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF 
unless transm itted to the sponsor or designee electronically  (eg, laboratory  data). The 
investigator is responsible for verify ing that data entries are accurate and correct by  
[CONTACT_55896] y or electronically signing the CRF.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory  agency  inspections and provide direct access to source data documents.
Monitoring de tails describing strategy  (eg, risk- based initiatives in operations and 
quality  such as Risk Management and Mitigation Strategies and Anal ytical Risk -
Based Monitoring), methods, responsibilities and requirements, including handling of 
noncompliance issues and monitoring techniques (central, remote, or on -site 
monitoring) are provided in the Monitoring Plan.
The sponsor or designee is responsible for the data management of this study  
including qualit y checking of the data.
The sponsor assumes accountability  for actions delegated to other individuals (eg, 
Contract Research Organizations).
Study  monitors will perform ongoing source data verification to confirm that data 
entered into the CRF b y authorized site personnel are accurate, complete, and 
verifiable fro m source documents; that the safet y and rights of participants are being 
protected; and that the study  is being conducted in accordance with the currentl y 
approved protocol and any other stud y agreements, I CH GCP, and all applicable 
regulatory  requirements.
Records and documents, including signed ICFs, pertaining to the conduct of this study  
must be retained b y the investigator for 15years after study  completion unless local 
regulations or institutional policies require a longer retention period. No records may  
be destro yed during the retention period without the written approval of the sponsor. 
No records may  be transferred to anothe r location or party without written notification 
to the sponsor.
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 34of 43
10.1.7 Source Documents
Source documents provide evidence for the existence of the participant and 
substantiate the integrity  of the data collected. Source documents are filed at the 
investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the source documents or the discrepancies must be explained. The investigator may need to request previous medical records or transfer records, depending on the study . Also, current medical records must be available.
10.1.[ADDRESS_815702] been collected and a study -site closure visit has been performed.
The investigator may  initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
Reasons for the earl y closure of a stud y site b y the sponsor or investigator may include but are 
not limited to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines
10.1.9 Publication Policy
Not applicable . It is not planned to publish data from this study , it might be that rollover study  
data will contribute to publications on feeder study data.
10.2 Appendix 2: Clinical Laboratory Tests
Not applicable as no blood samples will be taken in this rollover study . 
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting
10.3.1 Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study participant, 
temporally associated with the use of study  intervention, whether or not considered 
related to the stud y intervention.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (eg, ECG, radiological scans, vital signs measurements), 
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 35of 43
Events Meeting the AE Definition
including those that worsen from baseline, considered clinicall y significant in the 
medical and sc ientific judgment of the investigator (ie, not related to progression of 
underly ing disease).
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detec ted or diagnosed after study  intervention administration even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is an intentional overdose taken with possible suicidal/self -
harming intent. Such overdoses should be reported regardless of sequelae.
The signs, s ymptoms, and/or clinical sequelae resulting from lack of efficacy  will be 
reported as AE or SAE if they  fulfil the definition of an AE or SAE. Also, “lack of 
efficacy ” or “failure of expected pharmacological action” also constitutes an AE or 
SAE.
Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_11009]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the participant’s condition.
Medical or surgical procedure (eg, endoscopy , appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre -existing di sease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
10.3.2 Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study , death 
due to progression of disease).
An SAE is defined as any untoward medical occurrence that, at any dose:
1.Results in death
Is life -threatening
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ADDRESS_815703] caused death, if it were more severe.
Requ ires inpatient hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_19949] (usually involving 
at least an overnight stay) at the hospi[INVESTIGATOR_294504]/or 
treatment that would not have been appropriate in the phy sician’s office or outpatient 
setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a complication prolongs 
hospi[INVESTIGATOR_23919], the event is serious . When in doubt as to 
whether “hospi[INVESTIGATOR_059]” occurred or was necessary , the AE should be considered serious.
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen from baseline is not considered an AE.
Results in persis tent disability/incapacity
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated head ache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) which may  interfere with or prevent 
every day life functions but do not constitute a substantial disruption.
Is a congenital anomaly/birth defect
Other situations:
Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that 
may not be immediatel y life-threatening or result in death or hospi[INVESTIGATOR_217611]. These events should usually  
be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency  
or drug abuse.
10.3.3 Recording and Follow -Up of AE and/or SAE
AE and SAE Recording
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory  reports, and diagnostics 
reports) related to the event.
The investigator will then record all relevant AE (those AEs leading to dose 
reduction, interruption/delay  and discontinuation and any  new Any  new CTCAE 
version 5.[ADDRESS_815704] vital organs [e.g. heart, 
liver]) andall SAE information in the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to the medical monitor or Bay er’s pharmacovigilance department in 
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 37of 43
lieu of completion of the completed /AE/SAE CRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y the medical monitor or Bay er’s pharmacovigilance department . In this 
case, all participant identifiers, with the exception of the participant number, will be 
redacted on the copi[INVESTIGATOR_614962]’s pharmacovigilance department .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported during 
the study  and assign it as per CTCAE Ver 5.0.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE/SAE.
A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as wel l as the temporal relationship of the event to study  intervention 
administration will be considered and investigated.
The investigator will also consult the Investigator’s Brochure (IB) and/or Product Information, for marketed products, in his/her assessme nt.
For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to i nclude in the initial report to Bayer’s pharmacovigilance 
department . However, it is very important that the investigator always make an 
assessment of causality for every event before the initial transmission of the SAE data to Bayer’s pharmacovigilance de partment .
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send an SAE follow- up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 38of 43
Follow -up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  [CONTACT_8996]’s 
pharmacovigilance department to elucidate the nature and/or causalit y of the AE or 
SAE as fully  as possible. This may  include additional laboratory  tests or 
investigations, histopathological examinations, or consultation with other health care professionals.
If a participant dies dur ing participation in the study  or during the safety  follow -up 
period, the investigator will provide the medical monitor and/or Bayer’s pharmacovigilance department with a copy  of any  post- mortem findings including 
histopathology , if applicable. 
New or upd ated information will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to the Bayer’s 
pharmacovigilance department within 24 hours of receipt of the information.
10.3.4 Reporting of SAEs
SAE Reporting to Bayer’s pharmacovigilance department via an Electronic Data 
Collection Tool
The primary  mechanism for reporting an SAE to Ba yer’s pharmacovigilance 
department will be the electronic data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool (see next section) in order to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
After the stud y is completed at a given site, the electronic data collection tool will 
be taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously reported SAE after the electroni c data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next section) .
Contacts for SAE reporting can be found in in the SAE paper template .
SAE Reporting to Bayer’s pharmacovigilance department via Paper CRF
Facsimile transmission of the SAE paper CRF is the preferred method to transmit 
this information to the Bayer’s pharmacovigilance department.
In rare circumstances and in the absence of facsimile equipment, notification by  
[CONTACT_181813] a copy  of the SAE report sent b y overnight mail or 
courier service.
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 39of 43
SAE Reporting to Bayer’s pharmacovigilance department via Paper CRF
Contacts for SAE reporting can be found in the SAE paper template.
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 40of 43
10.4 Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information
Definitions:
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming post -menopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before first dose of study intervention, additional evaluation should be 
conside red.
Women in the following categories are not considered WOCBP
1.Premenarchal
2.Premenopausal female with 1 of the following:
Documented h ysterectomy
Documented bilateral salpi[INVESTIGATOR_1656]
Documented bilateral oophorectom y
For individuals with permanent infertility  due to an alternate medical cause other than 
the above, (eg, mullerian agenesis, androgen insensitivity ), investigator discretion 
should be applied to determining study  entry .
Note: Documentation can come from the site personnel’s: review of th e participant’s 
medical records, medical examination, or medical history  interview.
3.Postmenopausal female
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. 
A high follicle stimulating hormone (FSH) level in the postmenopausal 
range may  be used to confirm a postmenopausal state in women not using 
hormonal contraception or hormonal replacement therap y (HRT). 
However, in the absence of 12 months of amenorrhea, confirmation with 
more than one FSH measurement is required. 
Females on HRT and whose menopausal status is in doubt will be required to use one of the non -estrogen hormonal highl y effective contraception methods if they 
wish to continue their HRT during the stud y. Otherwise, they must discontinue 
HRT to a llow confirmation of postmenopausal status before study  enrollment.
Collection of Pregnancy  Information
Male participants with partners who become pregnant
The investigator will attempt to collect pregnancy  information on any  male 
participant’s female par tner who becomes pregnant while the male participant is in 
this study . This applies only  to male participants who receive regorafenib.
After obtaining the necessary  signed informed consent from the pregnant female 
partner directl y, the investigator will re cord pregnancy  information on the appropriate 
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 41of 43
form and submit it to the sponsor within 24 hours of learning of the partner’s 
pregnancy . The female partner will also be followed to determine the outcome of the 
pregnancy . Information on the status of the mot her and child will be forwarded to the 
sponsor. Generally , the follow -up will be no longer than 6 to 8 weeks following the 
estimated delivery  date. Any  termination of the pregnancy  will be reported regardless 
of fetal status (presence or absence of anomali es) or indication for the procedure. 
Female Participants who become pregnant
The investigator will collect pregnancy  information on any  female participant who 
becomes pregnant while participating in this study. I nformation will be recorded on 
the appropri ate form and submitted to the sponsor within 24 hours of learning of a 
participant's pregnancy . 
The participant will be followed to determine the outcome of the pregnancy . The 
investigator will collect follow -up information on the participant and the neon ate, after 
obtaining the signed informed consent from both parents of the neonate, unless local 
law or specific circumstances of the respective case allow otherwise ,and the 
information will be forwarded to the sponsor. Generall y, follow- up will not be 
required for longer than 6 to 8 weeks bey ond the estimated delivery  date. Any  
termination of pregnancy will be reported, regardless of fetal status (presence or absence of anomalies) or indication for the procedure.
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complication or elective termination of a pregnancy will be reported as an AE or SAE. A spontaneous abortion is alway s considered to be an SAE and will be reported as 
such. An y post -study  pregnancy  related SAE considered rea sonably related to the 
study  intervention b y the investigator will be reported to the sponsor as described in 
Section 8.3.4. While the investigator is not obligated to activel y seek this information 
in former stud y participants, he or she may learn of an SAE through spontaneous 
reporting.
Any female participant who becomes pregnant while participating in the study will 
discontinue study  intervention and will be withdrawn from the stud y.
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 42of 43
10.5 Appendix 5: Abbreviations
AE Adverse event
ALT Alanine aminotransferase
AST Aspartate aminotransferase
AUC Area under the activity  curve
BCRP Breast cancer resistance protein
BP blood pressure
CFR Code of Federal Regulations
CIOMS Council for International Organizations of Medical Sciences
Cmax Maximum observed plasma concentration
CONSORT Consolidated Standards of Reporting Trials
CRC Colorectal carcinoma
CRF Case report form
CTCAE Common terminology  criteria for adverse events
CYP Cytochrome P450
CYP3A4 Cytochrome P450 3A4
DNA Deox y-ribonucleic acid
ECG electrocardiogram
ECOG Eastern Cooperative Oncology  Group
eCRF Electronic case report form
e.g. For example
EoT End of treatment
FSH Follicle stimulating hormone
GCP Good clinical practice
G-CSF Granulocy te colony -stimulating factor
GIST Gastrointestinal stroma
GMP Good Manufacturing Process
HCC Hepatocellular carcinoma
hCG Human chorionic gonadotropin
HFSR hand -foot-skin reaction
HRT Hormonal replacement therap y
IB Investigators brochure
IEC Independent ethics committee
ICF Informed consent form
ICH International conference on harmonization
i.e. id est; that is
IRB Institutional review board
PI [INVESTIGATOR_614963] -emergent adverse events
ULN upper limit of normal
WOCBP Women of childbearing potential
CONFIDENT IAL Clinical Study  Protocol 
BAY 73 -4506 / [ZIP_CODE]
Amendment 1 Page 43of 43
10.6 Appendix 6 CYP3A4 inducers and inhibitors 
Table 10–1 presents an overview of CYP3A4 inducers and strong CYP3A4 inhibitors. 
CYP3A4 inducers and strong CYP3A4 inhibitors are NOT allowed due to drug- drug-
interaction with regorafenib. 
Table 10–1 :  An overview of CYP3A 4 inducers and strong CYP3A 4 inhibitors 
STRONG CYP3A 4 Inhibitors CYP3A 4 Inducers
Boceprevir 
Clarithrom ycin 
Cobicistat, only available in the combination with elvitegravir, emtricitabine, tenofovir or disoproxil fumarate
Conivaptan Delavirdine Idelalisib Indinavir 
Itraconazole 
Ketoconazole Lopi[INVESTIGATOR_614964] (St John’s 
Wort) 
LersivirineLumacaftor 
Methylphenobarbital Mitotane Modafinil
Nafcillin
Phenobarbital Phenytoin Primidone 
Rifabutin
Rifampi[INVESTIGATOR_614965]3A4 inducers and strong CYP3A4 inhibitors in Table 10–1 were identified using the 
Bayer-World Health Organization’s Drug Dictionary  (WHO -DD) and Bayer drug groupi[INVESTIGATOR_388338]3A4 inducers and CYP3A4 inhibitors.
11. References
Not applicable.